1. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
- Author
-
Peggs, Karl S, Quezada, Sergio A, Korman, Alan J, and Allison, James P
- Subjects
- *
T cells , *ANTIGENS , *IMMUNE response , *ANTINEOPLASTIC agents - Abstract
Cytotoxic T lymphocyte antigen-4 has become recognized as one of the key negative regulators of adaptive immune responses, having a central role in the maintenance of peripheral tolerance and in shaping the repertoire of emergent T cell responses. Concurrent recognition of the potential importance of inhibitory immune regulators in limiting antitumor responses, either as a result of chronic antigenic stimulation or the self-nature of many tumor-selective target antigens, has led to the development of cytotoxic T lymphocyte antigen-4-blocking antibodies as therapeutic anticancer agents. Following extensive preclinical modeling, these agents have entered clinical trials, where they are showing encouraging activity in heavily pretreated patients with advanced-stage disease, particularly with melanoma or renal carcinoma. Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF